Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Teva Completes Cephalon Acquisition After Winning EU Approval

Teva Pharmaceutical Industries Ltd., the world’s largest generic drugmaker, completed its acquisition of Cephalon Inc. after it agreed to sell off a generic version of Cephalon’s biggest product, Provigil.

The divestment of a generic version of modafinil, the active ingredient in the narcolepsy treatment Provigil, “will allow a competitor to emerge and compete effectively” with the combined company, the European Commission said in an e-mailed statement today. Teva and Cephalon said yesterday that they won EU approval.

EU antitrust regulators are separately investigating Teva and Cephalon over a 2005 agreement that may have delayed generic versions of Provigil.

Teva, based in Petach Tikvah, Israel, agreed in May to buy Cephalon in a deal valued at $6.8 billion including assumed debt. The acquisition will help Teva offset the revenue it may lose as its top-selling product, the multiple-sclerosis drug Copaxone, faces competition from generic versions and new branded products.

The deal will add to earnings within the fourth quarter after closing, Teva said. Excluding costs linked to acquisitions, the acquisition will add to earnings immediately.

Acino Holding AG said today that it agreed to buy the Middle Eastern and African business of Cephalon for 60 million euros ($83 million) in cash and 20 million euros of new shares.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.